Les publications de recherche préclinique et clinique font autorité et constituent une ressource précieuse pour les professionnels de la santé qui s’intéressent à nos technologies et à leur application. Comme de nouvelles études sont régulièrement réalisées, la liste de références actualisée est accessible sur demande.

200+ Références
In vitro
Précliniques
Cliniques
Livres

Publications les plus significatives

Colonne vertébrale

The use of bioactive glass as a posterolateral graft in patients with infected spondylodesis.

Voorde P, Geurts J. J Case Rep Images Orthop Rheum 2019;4:100019Z14PV2019.

Novel bioactive glass putty (S53P4) as bone graft expander in minimally invasive lumbosacral interbody fusion.

Saarenpää I, Hirvonen J, Frantzén J. J Minim Invasive Spine Surg Tech. 2018;3(2):52-58.

The effect of bioactive glasses on spinal fusion: a cross-disciplinary systematic review and meta-analysis of the preclinical and clinical data.

Cottrill E, Pennington Z, Lankipalle N, Ehresman J, Valencia C, Schilling A, Feghali J, Perdomo-Pantoja A, Theodore N, Sciubba D, Witham T. 2020

Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone. A prospective 11-year follow-up.

Frantzén J, Rantakokko J, Aro H, Heinänen J, Kajander S, Gullichsen E, Kotilainen E, Lindfors NC. 2011

Chirurgie de la mastoïde

Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance.

Bernardeschi D, Law-ye B, Bielle F, Hochet B, Sterkers O, Dormont D, Pyatigorskaya N. Eur Radiol. 2019 Mar 19. doi: 10.1007/s00330-019-06120-z.

Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery.

de Veij mestdagh P, Colnot D, Borggreven P, Orelio C,Quak J. Acta Oto-Laryngologica. 2017;137(7):690-694.

Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass S53P4: a prospective clinical study.

Bernardeschi D, Pyatigorskaya N, Russo FY, De Seta D, Corallo G, Ferrary E, Nguyen Y, Sterkers O. Clin Otolaryngol. 2017;42(2):387-396.

Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.

Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelio C, Quak J. Eur Arch Otorhino-laryngol. 2017;274(12):4121-4126.

Précliniques

S53P4 bioactive glass scaffolds induce BMP expression and integrative bone formation in a critical-sized diaphysis defect treated with a single-staged induced membrane technique.

Eriksson E, Björkenheim R, Strömbergb G, Ainola M, Uppstud P, Aalto-Setälä L, Leino V-M, Hupa L, Pajarinen J, Lindfors N. Acta Biomaterialia 2021;126:463-76.

Polymer-coated bioactive glass S53P4 increases VEGF and TNF expression in an induced membrane model in vivo.

Björkenheim R, Strömberg G, Pajarinen J, Ainola M, Uppstu P, Hupa L, Böhling TO, Lindfors NC. Journal of Materials Science 2017;52(15):9055–65.

BAG S53P4 putty as bone graft substitute – a rabbit model.

Saarenpää I, Stoor P, Frantzén J. Biomed Glasses. 2017;3:30-40.

Tissue response to bioactive glass and autogenous bone in the rabbit spine

Lindfors NC, Aho AJ. Eur Spine J. 2000;9:30-35.

Traumatologie

Our short-term experience with the use of S53P4 (BonAlive®) bioactive glass as a bone graft substitute.

Gergely I, Nagy Ö, Zagyva A, Zuh SG, Russu OM, Pop TS. 2011

Bioactive glass S53P4 and autograft bone in treatment of depressed tibial plateau fractures. A prospective randomized 11- year follow-up.

Pernaa K, Koski I, Mattila K, Gullichsen E, Heikkilä J, Aho A, Lindfors N. J Long-term Eff Med Impl. 2011;21(2):139-48.

Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1 year follow-up study

Heikkilä JT, Kukkonen J, Aho AJ, Moisander S, Kyyrönen T, Mattila K. J Mater Sci: Mater Med. 2011;22(4):1073-1080.

Tumeur osseuse bénigne

Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors.

Lindfors NC, Heikkilä JT, Koski I, Mattila K, Aho A. 2009

Long-term evaluation of blood silicon and ostecalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone.

Lindfors NC, Heikkilä JT, Aho A. 2008

Treatment of Aneurysmal Bone Cysts With Bioactive Glass In Children

Syvänen J, Nietosvaara Y, Kohonen I, Koskimies E, Haara M, Korhonen J, Pajulo O, Helenius I. Scandinavian Journal of Surgery 2017;1–6.

A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors.

Lindfors NC, Koski I, Heikkilä JT, Mattila K, Aho AJ. J Biomed Mater Res. 2010;94B(1):157-64.

Infection osseuse

Evaluation of the clinical effectiveness of bioactive glass (S53P4) in the treatment of non-unions of the tibia and femur: study protocol of a randomized controlled non-inferiority trial.

Tanner MC, Heller R, Westhauser F, Miska M, Ferbert T, Fischer C, Gantz S, Schmidmaier G, Haubruck P. Trials. 2018;19(1):299.

Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review.

Bigoni M, Turati M, Zanchi N, Lombardo AS, Graci J, Omeljaniuk RJ, Zatti G, Gaddi D. Eur Rev Med Pharmacol Sci. 2019;23(2 Suppl):240-51.

Antibacterial bioactive glass, S53P4, for chronic bone infections – a multinational study.

Lindfors NC, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvönen P, Suda A, Domenico A, Artiaco S, Alizadeh C, Brychcy A, Bialecki J, Romano C. Adv Exp Med Biol. 2017;971:81-92.

The use of bioactive glass S53P4 as bone graft substitute in the treatment of chronic osteomyelitis and infected non-unions – a retrospective study of 50 patients.

Al Malat TA, Glombitza M, Dahmen J, Hax P-M, Steinhausen E. Z Orthop Unfall 2018; 156: 152–159.

Diabetic foot osteomyelitis

Possible advantages of S53P4 bioactive glass in the treatment of septic osteoarthritis of the first metatarsophalangeal joint in the diabetic foot.

Kastrin M, Rovan V, Frangež I. J. Clin. Med. 2021, 10(6), 1208.

Pilot experience on the use of S53P4 bioactive glass in the surgical management of diabetic foot osteomyelitis.

Iacopi E, Pieruzzi L, Goretti C, Piaggesi A. 2020

Bioactive glass S53P4: A new opportunity for the treatment in the diabetic foot osteomyelitis.

De Giglio R, Di Vieste G, Mondello T, Balduzzi G, Masserini B, Formenti I, Lodigiani S, Signorelli F, De Angelis G, Pallavicini D, Pintaudi B, Mazzone A. 2019

Efficacy and safety of bioactive glass S53P4 as a treatment for diabetic foot ostemyelitis.

De Giglio R, Di Vieste G, Mondello T, Balduzzi G, Masserini B, Formenti I, Lodigiani S, Pallavicini D, Pintaudi B, Mazzone A. J Foot Ankle Surg. 2020, doi: 10.1053/j.jfas.2020.06.029.